Merck-Endocyte exclusive worldwide agreement on vintafolide. $120M upfront, up to $880M in dev/reg/commercial milestones across 6 cancer indications. 50/50 US profit share, double-digit ex-US royalty. Phase 3 PROCEED trial in platinum-resistant ovarian cancer.